Literature DB >> 18541153

The Food and Drug Administration approves lubiprostone for irritable bowel syndrome with constipation.

Les Lang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18541153     DOI： 10.1053/j.gastro.2008.06.004

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  7 in total

1.  Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders.

Authors:  Gareth J Sanger; Lin Chang; Chas Bountra; Lesley A Houghton
Journal:  Therap Adv Gastroenterol       Date:  2010-09       Impact factor: 4.409

2.  Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome.

Authors:  Tisha N Lunsford; Lucinda A Harris
Journal:  Int J Womens Health       Date:  2010-10-27

Review 3.  Complementary and alternative medicines in irritable bowel syndrome: an integrative view.

Authors:  Oliver Grundmann; Saunjoo L Yoon
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

4.  Lubiprostone induced ischemic colitis.

Authors:  Muhammed Sherid; Humberto Sifuentes; Salih Samo; Parakkal Deepak; Subbaramiah Sridhar
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

5.  Effective Constipation Treatment Changes More Than Bowel Frequency: A Systematic Review and Meta-Analysis.

Authors:  Klaus Bielefeldt; David J Levinthal; Salman Nusrat
Journal:  J Neurogastroenterol Motil       Date:  2016-01-31       Impact factor: 4.924

Review 6.  Lubiprostone in the treatment of chronic idiopathic constipation: an update on health-related quality of life and patient-reported outcomes.

Authors:  Maham Hayat; Hassaan Zia; Salman Nusrat
Journal:  Patient Relat Outcome Meas       Date:  2019-02-12

7.  Pharmacological and non-pharmacological treatments for irritable bowel syndrome: Protocol for a systematic review and network meta-analysis.

Authors:  Shenghui Zhou; Xiaoli Liu; Xiaoxia Wang; Fenglin Xi; Xiaoke Luo; Liang Yao; Hao Tang
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.